Testosterone Replacement Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2012 – 2018 The testosterone replacement therapy is a process of giving testosterone when testes do not produce sufficient amount of testosterone because of injury, damage or absence. The testosterone replacement therapy has gained the momentum in last decade with high penetration in surgery market. The testosterone replacement therapy market could be segmented into 3 categories based on the type of product, into the following sub segments: gel, patches and other. Increasing awareness of testosterone treatment and hypogonadism and increasing surging aging populace with high disposable will drive this market. This market is expected to expand with strong promotional activities from pharmaceutical companies to educate patients and physicians. Gel segment hold the lion’s share in term of value sale. With Introduction of new formulation like Axiron, Bio-T-Gel and Androgel 1.62% gel segment is expected to grow further. Browse Full Report: Testosterone Replacement Therapy Market TRT is the less aware technology in the market which needs the strong promotional activities to penetrate the large potential market. There is a large opportunity for TRT market in Asia-Pacific with more than 81 million of combined population in India and china is above the age of 65. Some of the major players in the testosterone replacement therapy market are: Endo Pharmaceuticals, Inc. Abbott Laboratories, Columbia Laboratories, Inc., Auxilium Pharmaceuticals, Inc., Eli Lilly and Company, Glaxo Smith Kline plc, Bayer Schering Pharma AG, Kyowa Hakko Kirin Co., Ltd, ProStrakan Group PLC., Trimel BioPharma SRL, Watson Pharmaceuticals, Inc. Acrux Limited, Slate Pharmaceuticals, Inc.,and others
This research report analyzes this market depending on its market segments, major geographies, and current market trends.